Amgen Inc. (NASDAQ:AMGN) Shares Sold by Antonetti Capital Management LLC

Antonetti Capital Management LLC lessened its stake in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 22.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,045 shares of the medical research company’s stock after selling 300 shares during the quarter. Antonetti Capital Management LLC’s holdings in Amgen were worth $281,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. OFI Invest Asset Management acquired a new position in shares of Amgen during the 3rd quarter worth $26,000. Briaud Financial Planning Inc acquired a new position in shares of Amgen during the 3rd quarter worth $26,000. IAG Wealth Partners LLC grew its stake in shares of Amgen by 520.0% during the 2nd quarter. IAG Wealth Partners LLC now owns 124 shares of the medical research company’s stock worth $28,000 after purchasing an additional 104 shares during the period. VisionPoint Advisory Group LLC purchased a new stake in shares of Amgen in the 2nd quarter worth about $28,000. Finally, Strategic Investment Solutions Inc. IL purchased a new stake in shares of Amgen in the 1st quarter worth about $28,000. 74.44% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Up 0.1 %

AMGN traded up $0.22 on Monday, reaching $291.34. 497,042 shares of the company’s stock were exchanged, compared to its average volume of 2,938,014. The company’s 50 day moving average is $295.30 and its 200-day moving average is $274.74. The company has a market cap of $155.92 billion, a price-to-earnings ratio of 23.42, a PEG ratio of 2.74 and a beta of 0.62. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65.

Amgen (NASDAQ:AMGNGet Free Report) last posted its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The firm had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company’s revenue was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.09 EPS. Equities analysts predict that Amgen Inc. will post 19.54 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 7th. Investors of record on Friday, February 16th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date is Thursday, February 15th. This is an increase from Amgen’s previous quarterly dividend of $2.13. Amgen’s dividend payout ratio is 68.21%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,096 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $273.03, for a total value of $572,270.88. Following the completion of the sale, the senior vice president now owns 10,874 shares of the company’s stock, valued at $2,968,928.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.57% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of several recent research reports. Truist Financial reiterated a “buy” rating and issued a $320.00 price objective on shares of Amgen in a research report on Wednesday, November 29th. Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $264.00 to $320.00 in a research report on Thursday, December 21st. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Amgen in a research report on Thursday, November 9th. They issued a “hold” rating and a $240.00 price objective on the stock. SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $324.00 to $318.00 in a research report on Wednesday, February 7th. Finally, UBS Group reduced their target price on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating on the stock in a report on Monday, January 29th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average price target of $295.30.

Read Our Latest Report on Amgen

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Read More

Want to see what other hedge funds are holding AMGN? Visit to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.